VOR BIOPHARMA INC. - COMMON STOCK

Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

08 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

Vor Bio Announces $55.6 Million Private Placement

27 Dec 2024 08:00:15 By Nasdaq GlobeNewswire

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

09 Dec 2024 06:30:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in the Stifel 2024 Healthcare Conference

12 Nov 2024 07:00:02 By Nasdaq GlobeNewswire

Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update

07 Nov 2024 15:05:01 By Nasdaq GlobeNewswire

Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

30 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies

05 Sep 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update

08 Aug 2024 15:05:02 By Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

02 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

09 Jul 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

04 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio Reports First Quarter 2024 Financial Results and Provides Company Update

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

02 May 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update

20 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

05 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Vor Bio to Participate in Upcoming Investor Conferences

04 Mar 2024 07:00:00 By Nasdaq GlobeNewswire